BIOTRONIK has agreed to sell its Vascular Intervention division to Teleflex Incorporated as part of a strategic focus on active implantable medical devices and digital health solutions.
Target Information
BIOTRONIK is a globally recognized leader in medical technology, specializing in cardiovascular, endovascular, and neuromodulation solutions. With a commitment to enhancing patient care through cutting-edge technologies, the company aims to improve clinical workflows using innovations such as Artificial Intelligence (AI), remote patient monitoring, and connected health platforms. These advancements are set to enhance efficiency in healthcare delivery and empower healthcare providers to offer personalized, cost-effective treatments.
In line with this strategic vision, BIOTRONIK has signed an agreement to sell its Vascular Intervention (VI) division to Teleflex Incorporated (NYSE: TFX), a leading provider of medical technology products worldwide. This transaction is expected to close by the third quarter of 2025, pending regulatory approvals, with both companies collaborating closely to ensure a smooth transition and favorable outcome.
Access Full Deal Insights
You’re viewing a public preview of this deal. To unlock full access to ca. 50,000 other deals in our database and join ca. 400 M&A professionals who are using it daily, sign up for Dealert.
Industry Overview
The medical technology industry in Germany, where BIOTRONIK is headquartered, is characterized by its rapid innovation and focus on improving patient outcomes. Germany boasts a well-established healthcare system, and its medical device sector is known
Similar Deals
Teleflex Incorporated
invested in
Vaskuläre Intervention (VI) business unit of BIOTRONIK
in 2025
in a Merger deal